Evaluating and Assessing Dabigatran Drug Interactions
Dabigatran is a novel oral direct thrombin inhibitor that has been shown to have beneficial outcomes in the prevention of thromboembolic stroke in patients with atrial fibrillation. Its advantages compared with warfarin may include decreased laboratory monitoring (e.g., international
normalized ratio), minimal cytochrome P450 drug interactions, lack of dietary interactions, and faster onset of action. However, dabigatran is still associated with drug interactions, as will be reviewed through a patient case. Consultant pharmacists should carefully review a patient&s
medication profile and evaluate the pros and cons of dabigatran therapy as its use becomes more prevalent.
Keywords: AF = Atrial fibrillation; Anticoagulation; Atrial fibrillation; CHADS2 = Congestive Heart Failure, Hypertension, Age, Diabetes, and Stroke; Clcr = Creatinine clearance; Dabigatran; Dronedarone; Drug interaction; INR = International normalized ratio; NSAID; NSAID = Nonsteroidal anti-inflammatory drug; P-gp = P-glycoprotein; St. John's wort
Document Type: Research Article
Publication date: 01 July 2012
- The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- ">
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content